Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex in Ataxia Telangiectasia
NCT06193200Phase 3Completed
- Sponsor
- IRulya Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 3 trial of dexamethasone sodium phosphate in ataxia-telangiectasia (AT), sponsored by IRulya Therapeutics. Started Jun 2024; status: completed.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT06193200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193200.